🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

RecruitingPhase 2Ages 18 Years - 85 YearsAllSecond Affiliated Hospital of Guangzhou Medical U…
NCT04803318 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

To study the clinical effect of Trametinib combined with Everolimus and Lenvatinib in the treatment of Recurrent/Refractory advanced solid tumors.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Recurrent/Refractory advanced solid tumors * Age between 18 and 85 years * Expected life expectancy is greater than three months Exclusion Criteria: * Benign tumor * Life expectancy is less than three months * Serious medical commodities * others
💊

What it tests

  • Combination of three inhibitors Trametinib, Everolimus and Lenvatinib
📍

Where

1 site
The Second Affiliated Hospital of Guangzhou Medical University
Guangzhou, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy